sciencenewsnet.in

MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer

April 14, 2021 sarah Jonas Boehringer Ingelheim, KRAS, Lung Cancer, MD Anderson Cancer Center

MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.

Announcement

UCLA team receives $6 million from NIH to explore new pancreatic cancer therapies

March 25, 2021 sarah Jonas Award, Cancer, Clinical Trial, Grant, KRAS, NIH Award, Pancreatic Cancer

A team of researchers from the UCLA Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health to identify new ways to treat pancreatic cancer.

Announcement

MD Anderson and Mirati Therapeutics announce KRAS strategic research and development collaboration in solid tumors

February 10, 2021 sarah Jonas Cancer, Colorectal Cancer, Gynecologic Cancer, KRAS, KRAS mutation, Lung Cancer, MD Anderson Cancer Center, Pancreatic Cancer, Targeted Therapy

The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.

Research Results

Researchers find protein promotes cancer, suppresses anti-tumor immunity

December 2, 2019 sarah Jonas 0 Comments Growth Factor, Immunotherapy, KRAS, Lung Cancer, Md Anderson, MD Anderson Cancer Center Houston, PD-L1, SUN

Researchers at The University of Texas MD Anderson Cancer Center have found that a protein involved in immune response to microbes, TBK1, also can fuel cancer development and suppress immune response to the disease.

Research Results

Boehringer Ingelheim and MD Anderson form unique virtual research and development center to rapidly advance new cancer therapies

August 12, 2019 sarah Jonas 0 Comments Cancer, Cancer Therapies, Cancer Treatment, Gastrointestinal Cancer, KRAS, Lung Cancer, MD Anderson Cancer Center, Moon Shots Program

Boehringer Ingelheim and MD Anderson have announced a new multi-year partnership to conduct collaborative research, combining the drug-development capabilities of MD Anderson with the pipeline of novel medicines from Boehringer Ingelheim.